INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 158 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,463,922 | -47.5% | 141,174 | -32.3% | 0.00% | -40.0% |
| Q2 2023 | $8,499,205 | +40.6% | 208,416 | +28.5% | 0.01% | +66.7% |
| Q1 2023 | $6,046,536 | +11.3% | 162,236 | +4.2% | 0.00% | 0.0% |
| Q4 2022 | $5,432,722 | -33.8% | 155,710 | +6.2% | 0.00% | -40.0% |
| Q3 2022 | $8,208,000 | +55.3% | 146,666 | +43.6% | 0.01% | +66.7% |
| Q2 2022 | $5,286,000 | -49.4% | 102,126 | -29.0% | 0.00% | -40.0% |
| Q1 2022 | $10,448,000 | -51.9% | 143,763 | -21.8% | 0.01% | -50.0% |
| Q4 2021 | $21,731,000 | -11.5% | 183,794 | +0.5% | 0.01% | -16.7% |
| Q3 2021 | $24,545,000 | -10.7% | 182,963 | +7.7% | 0.01% | -7.7% |
| Q2 2021 | $27,500,000 | +161.1% | 169,847 | +29.4% | 0.01% | +116.7% |
| Q1 2021 | $10,532,000 | +74.9% | 131,217 | +18.5% | 0.01% | +50.0% |
| Q4 2020 | $6,022,000 | +767.7% | 110,717 | +216.7% | 0.00% | – |
| Q3 2020 | $694,000 | -61.6% | 34,965 | -59.3% | 0.00% | -100.0% |
| Q2 2020 | $1,805,000 | +101.2% | 85,854 | +17.0% | 0.00% | 0.0% |
| Q1 2020 | $897,000 | -49.6% | 73,394 | -39.5% | 0.00% | 0.0% |
| Q4 2019 | $1,779,000 | +19.2% | 121,334 | +8.4% | 0.00% | 0.0% |
| Q3 2019 | $1,493,000 | -59.3% | 111,937 | -50.1% | 0.00% | -50.0% |
| Q2 2019 | $3,669,000 | +281.0% | 224,228 | +296.7% | 0.00% | +100.0% |
| Q1 2019 | $963,000 | -88.9% | 56,521 | -91.1% | 0.00% | -83.3% |
| Q4 2018 | $8,680,000 | -63.3% | 635,956 | -23.0% | 0.01% | -14.3% |
| Q3 2018 | $23,642,000 | +38.2% | 826,102 | +32.1% | 0.01% | +40.0% |
| Q2 2018 | $17,113,000 | +130.4% | 625,537 | +77.5% | 0.01% | +25.0% |
| Q1 2018 | $7,429,000 | +828.6% | 352,364 | +744.1% | 0.00% | +300.0% |
| Q4 2017 | $800,000 | -16.1% | 41,744 | +8.5% | 0.00% | 0.0% |
| Q3 2017 | $954,000 | +121.9% | 38,465 | +42.6% | 0.00% | – |
| Q2 2017 | $430,000 | +1620.0% | 26,966 | +1325.3% | 0.00% | – |
| Q1 2017 | $25,000 | -56.1% | 1,892 | -57.4% | 0.00% | – |
| Q4 2016 | $57,000 | +21.3% | 4,438 | +57.3% | 0.00% | – |
| Q3 2016 | $47,000 | -72.0% | 2,821 | -64.4% | 0.00% | – |
| Q2 2016 | $168,000 | – | 7,932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |